AstraZeneca stock heads into the open after a 2.0 percent drop

AstraZeneca stock closed at USD 156.89 on the NYSE on September 9, 2026, down 1.97 percent from the previous session.

September 9, 2026 in numbers

AstraZeneca PLC (ISIN GB0009895292, NYSE: AZN) ended the September 9, 2026 session at USD 156.89 on the NYSE, compared with a prior close of USD 160.04, marking a 1.97 percent decline for the day. Per NYSE quote data, the stock traded within a session range that kept the close between the day low and high, and daily volume stayed in line with its recent average. In the same session, the S&P 500 index slipped 0.6 percent, indicating that AstraZeneca underperformed the broader market.

According to Investing.com, RBC Capital initiated coverage of AstraZeneca with an Outperform rating and set a price target of GBP 145.00 on September 9, 2026, providing a supportive medium term view despite the short term share price decline. In addition, The Globe and Mail reported that on September 7, 2026 AstraZeneca announced US Food and Drug Administration accelerated approval for Etcamah (camizestrant) in combination with a CDK4/6 inhibitor as a first line treatment for certain HR positive, HER2 negative metastatic breast cancer patients, adding a notable pipeline milestone to the stock’s backdrop.

Pipeline news frames today

As The Globe and Mail noted, the FDA’s accelerated approval for AstraZeneca’s Etcamah combination in HR positive, HER2 negative metastatic breast cancer on September 7, 2026 gives the stock a fresh regulatory catalyst heading into today’s session. This approval in a major oncology indication can influence sentiment around AstraZeneca’s growth profile and its competitive position in hormone receptor positive breast cancer therapy. In parallel, broader equity markets remain sensitive to macro developments, with the S&P 500 having closed lower on September 9, 2026, a backdrop that can shape trading conditions for AstraZeneca today.